The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C

Gastroenterology

Volumn 119, Issue 5, 2000, Pages 1317-1323

  McHutchison, John G ^a   Poynard, Thierry ^b   Pianko, Stephen ^a   Gordon, Stuart C ^c   Reid, Andrea E ^d   Dienstag, Jules ^d   Yao, Ruji ^f   Albrecht, Janice ^f  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Service de Informatique   (France)

^c WILLIAM BEAUMONT HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; ETHNOLOGY; FEMALE; GENETICS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MIDDLE AGED; NEGRO; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; VIROLOGY;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ANTIVIRAL AGENTS; DRUG COMBINATIONS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RIBAVIRIN; RNA, VIRAL;

EID: 0034322373     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2000.19289     Document Type: Article

References (26)

1. Alter M, Kruszon-Moran D, Nainan 0, et al. The prevalence of hepatitis C virus in the United States, 1988 through 1994. N Engl J Med 1999:341:556-562.
2. Anonymous. National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C. Hepatology 1997;26(suppl 1):2S-10S.
3. Detre K, Belle S, Lombardero M. Liver transplantation for chronic viral hepatitis. Viral Hepat Rev 1996;2:219-228.
4. Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998;280:2088-2093.
5. Koff RS. Therapy of hepatitis C: cost-effectiveness analysis. Hepatology 1997;26:152S-155S.
6. Koff RS. Impaired health-related quality of life in chronic hepatitis C: the how, but not the why. Hepatology 1999;29:277-279.
7. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with Interferon therapy. The Consensus Interferon Study Group. Hepatology 1999; 29:264-270.
8. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of Interferon alpha 2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999:30:13181324.
9. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:14261432.
10. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492.
11. Rajender Reddy K, Hoofnagle J, Tong M, et al. Racial differences in responses to therapy with Interferon in chronic hepatitis C. Hepatology 1999:30:787-793.
12. El-Sarag H, Mason A. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
13. Frieden TR, Ozick L, McCord C, et al. Chronic liver disease in central Harlem: the role of alcohol and viral hepatitis. Hepatology 1999;29:883-888.
14. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435.
15. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994:20:15-20.
16. Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A. Prediction of response during Interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997:26:1640-1645.
17. Stuyver L, Rossau R, Wuseur A, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993:74:1093-1102.
18. Martinot-Peignoux M, Marcellin P, Pouteau M, étal. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to Interferon alfa therapy in chronic hepatitis C. Hepatology 1995:22:1050-1056.
19. Davis G, Lau J. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26(suppl 1):122S127S.
20. Smuts HE, Kannemeyer J. Genotyping of hepatitis C virus in South Africa. J Clin Microbiol 1995:33:1679-1681.
21. Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997:113:1660-1667.
22. Gaskin R. Diet, diabetes, hypertension and blacks. Ethnicity Dis 1999;9:272-277.
23. Powers DR, Wallin JD. End-stage renal disease in specific ethnic and racial groups: risk factors and benefits of antihypertensive therapy. Arch Intern Med 1998:158:793-800.
24. Gibbs CR, Beevers DG, Lip GY. The management of hypertensive disease in black patients. Q J Med 1999:92:187-192.
25. Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 1999; 341:1198-1205.
26. Shavers-Hornaday VL, Lynch CF, Burmeister LF, Torner JC. Why are African Americans under-represented in medical research studies? Impediments to participation. Ethnicity Health 1997;2: 31-45.